By Tristan
BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG
BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.
